Regarding the activation marker CD69, both in CD19+ B lymphocytes and in CD3+CD4+ T lymphocytes, the group with squamous cell carcinoma presented higher percentages, with p indicating differences for CD19+ B lymphocytes (p = 0.01) and T lymphocytes CD3+CD4+ (p = 0.03). This evidence concerns the gene CD19 and squamous cell carcinoma.